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Objective: To assess outcomes after endovascular abdominal aortic aneurysm repair (EVAR) in an integrated health care
system.
Methods: Between 2000 and 2010, 1736 patients underwent EVAR at 17 centers. Demographic data, comorbidities, and
outcomes of interest were collected. EVAR in patients presenting with ruptured or symptomatic aneurysms was cate-
gorized as urgent; otherwise, it was considered elective. Primary outcomes were mortality and aneurysm-related mortality
(ARM). Secondary outcomes were change in aneurysm sac size, endoleak status, major adverse events, and reintervention.
Results:Overall, the median age was 76 years (interquartile range, 70-81 years), 86% were male, and 82% were Caucasian.
Most cases (93.8%) were elective, but urgent use of EVAR increased from 4% in the ﬁrst 5 years to 7.3% in the last 5 years
of the study period. Mean aneurysm size was 5.8 cm. Patients were followed for an average of 3 years (range, 1-11 years);
8% were lost to follow-up. Intraoperatively, 4.5% of patients required adjunctive maneuvers for endoleak, ﬁxation, or
ﬂow-limiting issues. The 30-day mortality rate was 1.2%, and the perioperative morbidity rate was 6.6%. Intraoperative
type I and II endoleaks were uncommon (2.3% and 9.3%, respectively). Life-table analysis at 5 years demonstrated
excellent overall survival (66%) and freedom from ARM (97%). Postoperative endoleak was seen in 30% of patients and
was associated with an increase in sac size over time. Finally, the total reintervention rate was 15%, including 91 instances
(5%) of revisional EVAR. The overall major adverse event rate was 7.9% and decreased signiﬁcantly from 12.3% in the ﬁrst
5 years to 5.6% in the second 5 years of the study period (P < .001). Overall ARM was worse in patients with post-
operative endoleak (4.1% vs 1.8%; P < .01) or in those who underwent reintervention (7.6% vs 1.6%; P < .001).
Conclusions: Results from a contemporary EVAR registry in an integrated health care system demonstrate favorable
perioperative outcomes and excellent clinical efﬁcacy. However, postoperative endoleak and the need for reintervention
continue to be challenging problems for patients after EVAR. (J Vasc Surg 2013;58:324-32.)Since the ﬁrst endovascular repair of an abdominal
aortic aneurysm (AAA) in 1991,1 endovascular abdominal
aortic aneurysm repair (EVAR) has become the preferred
choice for AAA repair worldwide.2 Several randomized clin-
ical trials have demonstrated decreased early morbidity and
mortality with EVAR compared with traditional open
repair.3-6 However, long-term survival advantage and dura-
bility with EVAR have not been well established in compar-
ison to open surgical repair. Given the constant reﬁnement
of devices and technology, results from large trials oftenThe Permanente Medical Group, South San Franciscoa; the
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and are thus difﬁcult to compare to contemporary practice.7
Retrospective registries offer an opportunity to track
outcomes that may be more generalizable. However,
most large series arise from clinical trial registries8 or
come from institutional databases.9-11 With the exception
of several large series from high-volume centers,12-14 there
have been few large reported non-industry-afﬁliated regis-
tries in the U.S. This study examines utilization and
outcomes after EVAR in an integrated health care system.
METHODS
Kaiser Permanente is an integrated health care delivery
system that offers multispecialty care for more than
3 million members in Northern California. Since 2004,
implementation of digital health records has allowed access
to all arenas of clinical information. This study was a retro-
spective review of prospectively collected outcomes data for
EVAR performed in 17 medical centers in Northern Cali-
fornia from 2000 to 2010. This study protocol was
approved by the Kaiser Permanente Northern California
(KPNC) Institutional Review Board and was funded by
the KPNC Community Beneﬁt Research Grant Program.
Beginning in 2000, relevant clinical information for
patients undergoing EVAR was collected by trained
Fig 1. Evolving pattern of abdominal aortic aneurysm repair type
between 2000 and 2010 within Kaiser Permanente Northern Cal-
ifornia. EVAR, Endovascular abdominal aortic aneurysm repair.
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device selection, clinical success, and need for secondary
procedures was at the discretion of the operating surgeon.
Postoperative follow-up varied across medical centers but
generally involved a 1-month postoperative computed
tomography (CT) scan followed by serial CT imaging at
regular intervals accompanied by clinical follow-up.
Baseline demographic data were obtained from elec-
tronic data sources within KPNC. Device type was
collected from operative reports and device entry forms.
EVAR in patients presenting with ruptured or symptomatic
aneurysms at the preoperative CT scan was categorized as
“urgent.” All other EVAR was categorized as “elective.”
The primary outcome variables were all-cause mortality
and aneurysm-related mortality (ARM). ARM was deﬁned
as death within 30 days of the index EVAR or related
secondary procedure that was related to aneurysm rupture
or a major adverse event from the index EVAR.
Secondary outcome variables examined were occur-
rence of endoleak, need for reintervention, major adverse
events, and change in aneurysm sac size over time. Endo-
leak was classiﬁed according to established reporting stan-
dards.15 The presence of endoleak was ascertained from
clinical documentation and, when possible, the etiology
of the leak was listed. Aneurysm sac size was obtained
from imaging studies and clinical documentation. The
largest reported diameter was used as a single determinant
of aneurysm size.
Major adverse events were deﬁned as conversion to
open repair, aneurysm rupture, major embolic event, graft
infection requiring explantation, device migration, loss of
device patency requiring reintervention, and other miscella-
neous complications that signiﬁcantly impacted clinical
outcome. Device migration was reported if it required inter-
vention or if adequate seal was lost, usually when reduced to
less than 10 mm of the circumferential apposition length.
Statistical methods. All analyses were performed
using SAS 9.13 (SAS Institute Inc, Cary, NC). Rates of
various demographic and clinical characteristics were evalu-
ated with c2 tests or Fisher exact tests as appropriate for
categorical variables. Neither age at the index EVAR nor
preoperative AAA sac diameter were normally distributed;
therefore, nonparametric Wilcoxon-Mann-Whitney tests
were used to determine if any statistically signiﬁcant
difference existed between the elective and urgent groups.
Survival analysis was performed using the Kaplan-Meier
method to estimate the survival function with and
without stratiﬁcation. The log-rank test was used to com-
pare survival functions stratiﬁed by subgroups such as case
setting, gender, age, and aneurysm size. Cox proportional
hazards models were used to identify factors predictive of
death from any cause, death from aneurysm-related causes,
and need for reintervention, with the threshold of signiﬁ-
cance set at P < .05.
RESULTS
Demographics. From 2000 to 2010, 1736 patients
underwent primary EVAR at 17 medical centers withinthe health care system; during this time, there were 3382
open AAA repairs. The adoption of EVAR increased over
time compared with open AAA repair (Fig 1). Interest-
ingly, the total number of AAA repairs declined in the last 4
years of the study from over 500 in 2000 to just over 350
in 2010.
Baseline demographics and clinical characteristics are
listed in Table I. The majority of the EVAR patients were
male (86.5%), and 82.1% of patients were Caucasian. The
median age was 76 years (interquartile range [IQR], 70-
81 years), including 502 (28.9%) patients 80 to 89 years
old and 27 (1.6%) patients age 90 years or older. Nearly
94% of cases were done electively; 6% were performed
urgently (ruptured AAA, n ¼ 50; symptomatic AAA, n ¼
57). The proportion of urgent cases performed in the latter
part of the study period (2006-2010) increased signiﬁcantly
compared with the proportion in the early time period
(2000-2005; 7% vs 4%; P < .01). Mean aneurysm size
was 5.8 cm. Among the study cohort, 116 (6.7%) patients
underwent preoperative hypogastric artery embolization.
Selection of device type was at the discretion of the oper-
ating surgeon. The Cook Zenith (Cook Inc, Bloomington,
Ind) was used in close to half of all cases (n ¼ 841, 48.4%),
the Gore Excluder low permeability (W. L. Gore & Associ-
ates, Inc, Flagstaff, Ariz) was used in 25.2%, Medtronic
AneuRx (Medtronic Vascular, Santa Rosa, Calif) in
19.5%, and other approved or investigational devices in
6.8%. Bifurcated devices were used in 85% of patients,
with the remainder receiving aorto-uni-iliac devices with
femoral-femoral bypass as medically indicated.
Compared with patients who received surgery in an
elective manner, patients who received surgery in an urgent
setting tended to have larger aneurysms (6.3 cm [IQR,
5.5-7.9 cm] vs 5.6 cm [IQR, 5.2-6.2 cm]; P < .001),
more immediate complications (13% vs 6.2%; P < .01),
more major adverse events (16% vs 7.4%; P < .01), and
higher ARM (8 vs 2.1; P < .001). In addition, cases per-
formed urgently had a higher proportion of post-EVAR
rupture (8% vs 0.9%; P < .01).
Table I. Baseline preoperative demographic and clinical characteristics of 1736 EVAR patients, stratiﬁed by operative
indication
Characteristics a Total, No. (%)
Elective
(n ¼ 1629), No. (%)
Urgent
(n ¼ 107), No. (%) P valueb
EVAR year
2000-2005 595 (34.3) 571 (35.0) 24 (22) <.01
2006-2010 1141 (65.7) 1058 (65.0) 83 (78)
Males 1501 (86.5) 1415 (86.9) 86 (80) .06
Age, years .26c
Mean 6 SD 75.0 6 7.9 74.9 6 7.7 75.3 6 10.2
Median [IQR] 76.0 [70.0-81.0] 76.0 [70.0-80.0] 77.0 [69.0-82.0]
Age group, years
#79 1207 (69.5) 1146 (70.4) 61 (57) <.01
80-89 502 (28.9) 461 (28.3) 41 (38)
$90 27 (1.6) 22 (1.4) 5 (5)
Race/ethnicity group .13
Asian 122 (7.0) 113 (6.9) 9 (8)
Black 86 (5.0) 76 (4.7) 10 (9)
Hispanic 53 (3.1) 52 (3.2) 1 (1)
Caucasian 1426 (82.1) 1343 (82.4) 83 (78)
Unknown 49 (2.8) 45 (2.8) 4 (4)
Preoperative AAA size, cm <.001c
Mean 6 SD 5.8 6 1.1 5.7 6 1.0 6.6 6 1.7
Median [IQR] 5.6 [5.2-6.2] 5.6 [5.2-6.2] 6.3 [5.5-7.9]
Preoperative AAA size $5.5 cm 1027 (59.2) 944 (57.9) 83 (78) <.001
Coronary artery disease 810 (46.7) 769 (47.2) 41 (38) .07
Diabetes 442 (25.5) 415 (25.5) 27 (25) .96
Preoperative embolization 116 (6.7) 112 (6.9) 4 (4) .21
Hyperlipidemia 1324 (76.3) 1251 (76.8) 73 (68) .04
Hypertension 1455 (83.8) 1365 (83.8) 90 (84) .93
Peripheral vascular disease 367 (21.1) 345 (21.2) 22 (21) .88
Smoking
Never 1080 (62.2) 1007 (61.8) 73 (68) .26
Former 347 (20.0) 332 (20.4) 15 (14)
Current 309 (17.8) 290 (17.8) 19 (18)
Treated with statin 1156 (66.6) 1094 (67.2) 62 (58) .05
Bifurcated graft 1485 (85.5) 1391 (85.4) 94 (88) .48
AAA, Abdominal aortic aneurysm; EVAR, endovascular abdominal aortic aneurysm repair; IQR, interquartile range; SD, standard deviation.
aDue to rounding, group percentages may not total 100.
bFor comparisons between the elective and urgent groups.
cComparison result using Wilcoxon-Mann-Whitney test.
Table II. Unplanned intraoperative adjunctive maneuvers
during EVAR
Type Indication No. (%)
Aortic cuff/stent Proximal seal/ﬁxation 24 (1.4)






Branch vessel patency 14 (0.8)
Femoral-femoral bypass Limb compromise 3 (0.2)
EVAR, Endovascular abdominal aortic aneurysm repair; PTA, percutaneous
transluminal angioplasty.
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was 2 days (IQR, 1-3 days). Documented follow-up was
available for 91.9% of all patients throughout the study
period. The remaining 8.1% of patients lost to follow-up
declined surveillance, moved away, or left the health care
system. Overall, the median follow-up was 2.7 years
(IQR, 1.2-4.4 years). During this time, patients underwent
a median of four postoperative CT scans (IQR, 2-6 scans).
Perioperative outcomes. Overall, 4.5% of patients
required intraoperative adjunctive maneuvers for endoleak,
ﬁxation, or ﬂow-limiting issues, including three open
conversions (Table II). Reported intraoperative type I and
II endoleaks occurred in 2.3% and 9.3% of cases, respec-
tively. Of the 40 intraoperative type I leaks reported, all but
three were addressed by either standard or adjunctive
maneuver at the time of index EVAR. The immediate
complication rate was 6.6 % (Table III).
Major adverse events. Major adverse outcomes were
seen in 7.9% of patients and decreased signiﬁcantly
from 12.3% in 2000 to 2005 to 5.6% in 2006 to 2010(P < .001). There were 22 open conversions, 9 graft infec-
tions requiring graft removal, 7 major embolic events, 36
graft occlusions requiring treatment, 22 ruptures, and 40
cases of graft migration requiring intervention (Table IV).
Postoperative endoleak and reintervention. During
the study period, postoperatively detected endoleak was
Table III. Perioperative complications after EVAR





Limb thrombosis 9 (0.5)
Renal 7 (0.4)
Stroke 2 (0.1)
Unintended vessel occlusion 3 (0.2)
Vessel injury 23 (1.3)
Other 34 (2.0)
EVAR, Endovascular abdominal aortic aneurysm repair.
Table IV. Rates of adverse events and reinterventions
after EVAR
Events/interventions/outcomes No. (%)
Major adverse events (overall) 137 (7.9)
Open conversion 22 (1.3)
Major embolic event 7 (0.4)
Graft infection requiring explantation 9 (0.5)
Graft occlusion requiring treatment 36 (2.1)
Rupture 22 (1.3)
Graft migration requiring treatment 40 (2.3)
Other 28 (1.6)




Revisional EVAR 91 (5.2)
Endoleak-related major 73 (4.2)
Angiogram-related 172 (9.9)
EVAR, Endovascular abdominal aortic aneurysm repair.
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was signiﬁcantly higher in patients with an initial intraoper-
ative endoleak (treated or not) compared with patients
with no initial intraoperative endoleak (43.8% vs 28.1%;
P < .001). A total of 60 (3.5%) patients experienced a post-
operative type I leak, 474 patients (27.2%) had a type II
endoleak, and 16 patients had a type III leak.
Treatment strategies and outcomes differed by endo-
leak type. Operative treatment of type I leaks resulted in
ﬁve open conversions, with the remaining treatments con-
sisting of additional stent placement or conversion to an
aorto-uni-iliac device; one patient declined treatment. Of
the 474 patients with type II leaks, only 180 patients had
resolution by the second postoperative scan, whereas the
remaining patients had persistent leaks at 1 year or longer.
Five patients with type II endoleaks were treated opera-
tively with four open conversions and one hypogastric liga-
tion and stent extension. Of the 16 patients with
a presumed type III leak, there were three aorto-uni-iliac
conversions, three open conversions, and 13 cases of addi-
tional component placement (one patient had two such
procedures). Two patients with presumed type IV endo-
leaks underwent endograft relining.
The overall reintervention rate was 14.5% (n ¼ 251).
Of these, 103 patients had a single intervention, with the
remainder undergoing two or more interventions; 27
patients underwent 5 or more interventions. Most inter-
ventions were minimally invasive: 86.9% (218/251) of
patients underwent interventions that were endovascular
in nature, including 91 revisional EVARs. However, 73
patients required major operative leak-related interven-
tions. Reinterventions related to percutaneous angiography
numbered 172, including embolization of branch arteries
(n ¼ 71) and direct sac injection (n ¼ 25). Independent
predictors for reintervention included urgent indication,
postoperative leak (all types), pre-existing peripheral
vascular disease, and having undergone an intraoperative
adjunctive maneuver at the initial EVAR (Table V).
AAA diameter change over time. Overall, AAA sac
diameter was noted to decrease during the follow-up
period after EVAR. However, when stratiﬁed by endoleak
status and reintervention, variation was observed in AAA sac
size over time. Sac size began to increase in the second yearafter EVAR in those patients who experienced endoleaks
and underwent reintervention. In the absence of endoleak,
AAA sac size continued to decrease over time (Fig 2).
Survival. The overall 30-day mortality was 1.2%.
Octogenarians and nonagenarians had 30-day mortality
rates of 2.6% and 3.7%, respectively. Early mortality rates
were higher in patients operated on urgently (3.3% urgent
vs 1.0% elective; P < .05), females (2.1% vs 1.1% males; P <
.05), patients with large aneurysms (2.0% for AAAs $5.5
cm vs 0.1% for AAAs <5.5 cm; P < .001), and patients
with a major adverse event (6.6% vs 0.8%; P < .0001).
By life-table analysis, cumulative 5-year survival was
65.6% (Fig 3) and freedom from ARM was 96.6%. ARM
was worse in patients with postoperative endoleak (4.1%
vs 1.8%; P < .01) and in those undergoing reintervention
(7.6% vs 1.6%; P < .001).
Using multivariable analysis, we identiﬁed urgent indi-
cation, female gender, advanced age, and AAA size as inde-
pendent predictors of signiﬁcantly increased risk of both
all-cause mortality and ARM. The presence of any postop-
erative type I or III leak independently predicted increased
risk for ARM but not for all-cause mortality. Type II leaks,
while predictive of reintervention, did not increase the risk
of ARM. Conversely, those patients who underwent AAA
treatment without the need for subsequent reintervention
were protected with regard to ARM (Table V).
DISCUSSION
This study described long-term outcomes after EVAR
in a community-based setting during the ﬁrst decade of
experience with EVAR within our health care system.
The results demonstrated excellent 30-day mortality and
favorable rates of reintervention and freedom from ARM.
Time-dependent treatment trends showed a decline in
open AAA repair along with a concomitant rise in EVAR.
In addition, the use of EVAR for urgent indications
increased throughout the study period, likely as a result
of the gain in operator experience and comfort. We were









HR (95% CL) P value HR (95% CL) P value HR (95% CL) P value
Females 1.6 (1.2, 2.0) <.001 2.4 (1.2, 4.8) .02 1.3 (0.9, 1.9) .10
Age groups, years
#79a 1.0 1.0 1.0
80-89 2.2 (1.8, 2.6) <.001 2.6 (1.4, 5.1) <.01 1.2 (0.9, 1.5) .30
$90 3.8 (2.2, 6.7) <.001 3.9 (0.8, 19.2) .10 1.3 (0.5, 3.3) .53
Preoperative aneurysm size $5.5 cm 1.7 (1.4, 2.2) <.001 4.4 (1.7, 11.3) <.01 1.3 (1.0, 1.7) .10
Not on statin prior to EVAR 1.1 (0.9, 1.4) .40 0.9 (0.4, 2.0) .84 1.1 (0.8, 1.5) .56
Urgent EVAR 1.5 (1.0, 2.1) .03 2.7 (1.2, 6.2) .02 1.9 (1.2, 3.0) <.01
EVAR device
Zenitha 1.0 1.0 1.0
Gore 0.8 (0.6, 1.1) .13 1.5 (0.7, 3.4) .34 0.7 (0.5, 1.1) .11
Medtronic 1.0 (0.8, 1.3) .95 1.2 (0.5, 2.6) .71 1.2 (0.9, 1.6) .26
Others 1.2 (0.8, 1.7) .47 1.9 (0.6, 6.0) .27 1.6 (1.0, 2.6) .049
Coronary artery disease 1.2 (1.0, 1.5) .12 1.2 (0.6, 2.4) .57 1.0 (0.7, 1.3) .81
Diabetes 1.3 (1.0, 1.6) .05 1.3 (0.7, 2.7) .42 0.9 (0.7, 1.2) .51
Hyperlipidemia 0.7 (0.5, 0.9) <.01 1.0 (0.4, 2.3) .97 1.1 (0.7, 1.5) .74
Hypertension 1.2 (0.9, 1.6) .23 1.2 (0.4, 3.2) .78 1.0 (0.7, 1.5) .88
Peripheral vascular disease 1.3 (1.0, 1.6) .03 1.1 (0.5, 2.3) .82 1.5 (1.1, 2.1) <.01
Preoperative embolization 1.6 (1.1, 2.2) .01 2.3 (0.8, 6.6) .13 1.4 (0., 2.2) .18
Smoking
Nevera 1.0 1.0 1.0
Current 1.1 (0.8, 1.4) .62 1.2 (0.5, 3.1) .69 1.2 (0.8, 1.7) .40
Former 1.0 (0.8, 1.3) .92 0.9 (0.4, 2.1) .72 1.0 (0.7, 1.3) .77
Intraoperative endoleak
Nonea,b 1.0 1.0 1.0
Type I 0.8 (0.4, 1.5) .43 0.7 (0.1, 2.9) .58 0.9 (0.4, 1.9) .74
Type II 0.8 (0.6, 1.2) .36 1.1 (0.4, 3.2) .85 1.0 (0.6, 1.5) .84
Operative adjunctive maneuver 1.4 (0.9, 2.2) .18 1.4 (0.4, 4.8) .60 1.9 (1.1, 3.2) .02
Reinterventionb 1.5 (1.2, 2.1) <.01 0.4 (0.2, 0.8) .01 NA
Postoperative leak types I, III 1.2 (0.8, 1.9) .43 2.8 (1.2, 6.6) .02 4.2 (3.0, 5.9) <.001
Postoperative leak type II 1.1 (0.8, 1.3) .66 0.8 (0.4, 1.7) .63 3.4 (2.6, 4.5) <.001
CL, Conﬁdence limit; EVAR, endovascular abdominal aortic aneurysm repair; HR, hazard ratio.
aReferent group.
bUsed in the multivariable regression models for all-cause and aneurysm-related mortality only.
JOURNAL OF VASCULAR SURGERY
328 Chang et al August 2013interested to observe that the overall rate of AAA repair
declined throughout the study period. Pinpointing causa-
tive factors for this result was beyond the scope of this
study, but possible explanations include socioeconomic
factors (eg, less elective surgery because of the recent reces-
sion) as well as increased overall penetrance of statins and
smoking cessation efforts.
The strengths of this report lie in the excellent docu-
mented follow-up among EVAR patients and the contem-
porary nature of the results. Because a very small number of
these cases were performed within the context of a trial, the
results reﬂect a rich and varied practice pattern over a broad
geographic region. Unlike society-based registries, our
integrated health care system leverages existing systems to
automate and facilitate follow-up evaluation for patients
undergoing vascular reconstruction. For more than 10
years, KPNC has employed computerized tracking to
ensure that EVAR surveillance (along with several other
chronic conditions) is not overlooked, resulting in a near-
complete data set. As many who perform quality and audit-
ing activities will attest, achieving near-complete long-termfollow-up in patient registries is challenging. For example,
in a study looking at the impact of suboptimal surveillance
on outcome, Jones et al found a 32.8% incidence of incom-
plete follow-up after EVAR.16 This report presumed that in
these “missing” patients, adverse events were more likely to
have occurred.
In our study, the incidence of primary end points, such
as perioperative mortality and ARM, was comparable to that
seen in other cohorts. The cohort in the US OVER trial,
with recruitment occurring between 2002 and 2008,
more closely resembles our current cohort than those in
the older, European-based EVAR I, EVAR II, and
DREAM trials.4,17 However, the 30-day mortality rate in
the OVER trial was reported as 0.5%, and our results are
more similar to those reported in the EVAR I trial (1.8%),
Lifeline registry (1.7%), and a recent meta-analysis
(3.3%).4,8,18 The disparity in short-term mortality rate
between the OVER trial and our results may reﬂect the
nonexclusionary nature of our treated population.
Arguably the most important end point of EVAR treat-
ment, freedom from ARM, was achieved by nearly 97% of
Fig 2. Abdominal aortic aneurysm (AAA) sac size percent change among 1736 endovascular abdominal aortic
aneurysm repair (EVAR) patients from 2000 to 2010.
All-cause mortality
Time, year <1 1 2 3 4 5 6 7 8 9 10
No. entering interval, n 1736 1619 1258 946 677 437 266 163 99 56 25
No. of events, n  128 89 61 63 42 18 16 14 6 3 0
Cumulative survival 100% 92.1% 85.6% 80.1% 72.6% 65.6% 61.2% 55.2% 47.4% 42.3% 37.2%
Survival standard error 0% 0.7% 0.9% 1.1% 1.3% 1.6% 1.8% 2.2% 2.7% 3.1% 3.9%
Fig 3. All-cause Kaplan-Meier survival curve among 1736 endovascular abdominal aortic aneurysm repair (EVAR)
patients from 2000 to 2010.
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several series that included this end point. The Eurostar
registry reported 3% ARM (follow-up out to 8 years), the
EVAR arm of the DREAM trial (2 years after randomiza-
tion) reported 2.1%, and the OVER trial (mean follow-
up of 1.8 years) reported 1.4%.4,6,19 The improved ARM
in the OVER trial may reﬂect the later time period of
recruitment, physician experience, or improved device
design as compared with the earlier trial participants. In
the latter 5 years of our study period, we observed an
improvement in ARM that may similarly reﬂect overall
improved treatment. As expected, ARM was worse in
patients with any postoperative endoleak and in those
who went on to reintervention, so the decrease in ARM
corroborates the observed decrease in major adverse events
in the latter half of the study period.
Large retrospective registries incorporating multiple
facilities have allowed clinicians to examine contempora-
neous factors that may affect clinical outcome and represent
an important contribution to the EVAR knowledge base.
The largest EVAR registry in the U.S. described a combined
cohort of 2664 patients from four multicenter Investiga-
tional Device Exemption trials and compared them with
open surgical controls.8 This study led to signiﬁcant state-
ments about EVAR’s impact on AAA-related mortality
compared with open surgery in these trial patients. Impor-
tantly, this analysis did not include the Cook Zenith graft
and also included the AnCure device (Guidant, Indianapo-
lis, IN), which did not attain signiﬁcant long-term clinical
utilization. Similarly, the initial reports from the Eurostar
registry, which began in 1996, described several early
devices that were never approved in the U.S.,20 which
limits the generalizability of these results.
In this study, reintervention was reported in 14.5% of
patients, which is similar to multiple reports during the
same time period. We did not perform speciﬁc analyses of
the methods and indications for intervention, acknowl-
edging that the threshold for intervention varies by clini-
cian, surveillance regimen, and current practice trends.
Mehta et al reported a 19% reintervention rate at 2.8 years
in 1738 patients, which partially reﬂected their aggressive
approach to type II endoleak treatment.12 Other groups
have reported reintervention rates between 12% and
27%.21-24 In larger series, reintervention rates were also
comparable: Lifeline, 18% at 5 years; OVER, 14% at 1.8
years; and EVAR1, 23% at 5 years.4,8,25 The increased
ARM seen in the reintervention subgroup and the delayed
nature of many of these procedures serves to underscore
the need for long-term surveillance.
We observed worse outcomes in those patients treated
with EVAR for ruptured or symptomatic aneurysms than in
those who had elective treatment. Increases in all-cause
mortality, ARM, and need for reintervention all logically
followed the increased acuity of these patients. Further
research is needed to compare these outcomes to those
in patients undergoing open repair and to investigate
predictors of procedural success in these patients in order
to shed light on the utility of EVAR in this regard.The variables present in our integrated dataset allow
insight into the effect of patient risk factors on outcome
after EVAR. For example, our study demonstrated higher
30-day mortality for women compared with men. Other
authors have reported gender as an independent risk factor
for morbidity and mortality.26 Additional investigation into
this gender disparity will focus on anatomic and procedural
differences that might explain the mortality difference.
Further, in our multivariable analysis, advanced age,
gender, and larger aneurysms were independently found
to predict ARM. This is consistent with prior reports and
reinforces the need for continued study in these areas.
Interestingly, although presence of a postoperative type
II leak was found to predict intervention, it did not inde-
pendently predict increased ARM. This may suggest that
while not all type II leaks are benign, the majority of
them will not go on to cause signiﬁcant mortality. Statin
use, although well documented in the health record, was
not shown to have an effect on mortality outcome. This
is in contradistinction to data from 5892 patients in the
Eurostar registry, which suggested that statin use was inde-
pendently associated with reduced all-cause mortality after
EVAR.27 While the overall statin rate was 66.6%, the
greater incidence of hyperlipidemia suggests underutiliza-
tion of statins, especially early on in the study period.
One of the limitations of our study is the incomplete
collection of anatomic data or information regarding
adherence to Instructions for Use guidelines in our dataset,
which limited the ability to analyze outcomes across device
types. Varying practice patterns speciﬁc to a surgeon or
group of surgeons also limited our ability to comment on
rates of reintervention and patterns that might suggest
improved outcome. In addition, although outcome data
were collected prospectively, major events were self-
reported and were not adjudicated, thus raising the possi-
bility of an underreporting of adverse events. Future
work to more distinctly categorize these patients in our
dataset will allow better insight in future analyses.
In summary, as in many other health care delivery
systems, AAA repair in KPNC has changed signiﬁcantly in
recent years, with rapid adoption of EVAR and subsequent
excellent freedom from ARM. Further, our report high-
lights the advantages of our integrated health care delivery
system, in terms of facilitating long-term evaluation of the
effectiveness of new and evolving treatments. In the future,
we aim to expand our efforts toward national EVAR
surveillance within Kaiser Permanente, leveraging the
successful implementation of other national chronic disease
registries as a guide in these initiatives. Along with registry
efforts from the national vascular surgery societies, this will
allow clinicians to track important outcomes and provide
optimal care for patients undergoing AAA repair.AUTHOR CONTRIBUTIONS
Conception and design: RC, BH
Analysis and interpretation: RC, PG, BH, LT
Data collection: AR, NS, HH, SO
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 2 Chang et al 331Writing the article: NS, HH
Critical revision of the article: LT, SO, BH, AR
Final approval of the article: RC, LT, PG




1. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft
implantation for abdominal aortic aneurysms. Ann Vasc Surg 1991;5:
491-9.
2. Levin DC, Rao VM, Parker L, Frangos AJ. Endovascular repair vs open
surgical repair of abdominal aortic aneurysms: comparative utilization
trends from 2001 to 2006. J Am Coll Radiol 2009;6:506-9.
3. EVAR Trial Participants. Endovascular aneurysm repair versus open
repair in patients with abdominal aortic aneurysm (EVAR trial 1):
randomised controlled trial. Lancet 2005;365:2179-86.
4. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT Jr,
Matsumura JS, Kohler TR, et al. Outcomes following endovascular vs
open repair of abdominal aortic aneurysm: a randomized trial. JAMA
2009;302:1535-42.
5. Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR,
Balm R, et al. A randomized trial comparing conventional and endo-
vascular repair of abdominal aortic aneurysms. N Engl J Med
2004;351:1607-18.
6. Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J,
van Sterkenburg SM, et al. Two-year outcomes after conventional or
endovascular repair of abdominal aortic aneurysms. N Engl J Med
2005;352:2398-405.
7. Hopkins R, Bowen J, Campbell K, Blackhouse G, De Rose G,
Novick T, et al. Effects of study design and trends for EVAR versus
OSR. Vasc Health Risk Manag 2008;4:1011-22.
8. Lifeline Registry of EVAR Publications Committee. Lifeline Registry of
endovascular aneurysm repair: long-term primary outcome measures.
J Vasc Surg 2005;42:1-10.
9. Egorova N, Giacovelli J, Greco G, Gelijns A, Kent CK, McKinsey JF.
National outcomes for the treatment of ruptured abdominal aortic
aneurysm: comparison of open versus endovascular repairs. J Vasc Surg
2008;48:1092-100; 1100.e1-2.
10. Giles KA, Landon BE, Cotterill P, O’Malley AJ, Pomposelli FB,
Schermerhorn ML. Thirty-day mortality and late survival with rein-
terventions and readmissions after open and endovascular aortic
aneurysm repair in Medicare beneﬁciaries. J Vasc Surg 2011;53:6-12;
13 e11.
11. Schermerhorn ML, Giles KA, Sachs T, Bensley RP, O’Malley AJ,
Cotterill P, et al. Deﬁning perioperative mortality after open and
endovascular aortic aneurysm repair in the US Medicare population.
J Am Coll Surg 2011;212:349-55.
12. Mehta M, Sternbach Y, Taggert JB, Kreienberg PB, Roddy SP,
Paty PSK, et al. Long-term outcomes of secondary procedures after
endovascular aneurysm repair. J Vasc Surg 2010;52:1442-9.
13. Abbruzzese TA, Kwolek CJ, Brewster DC, Chung TK, Kang J,
Conrad MF, et al. Outcomes following endovascular abdominal aorticaneurysm repair (EVAR): an anatomic and device-speciﬁc analysis.
J Vasc Surg 2008;48:19-28.
14. Brewster DC, Jones JE, Chung TK, Lamuraglia GM, Kwolek CJ,
Watkins MT, et al. Long-term outcomes after endovascular abdominal
aortic aneurysm repair: the ﬁrst decade. Ann Surg 2006;244:426-38.
15. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg 2002;35:1048-60.
16. Jones WB, Taylor SM, Kalbaugh CA, Joels CS, Blackhurst DW,
Langan EM 3rd, et al. Lost to follow-up: a potential under-appreciated
limitation of endovascular aneurysm repair. J Vasc Surg 2007;46:
434-41.
17. Malas MB, Freischlag JA. Interpretation of the results of OVER in the
context of EVAR trial, DREAM, and the EUROSTAR registry. Semin
Vasc Surg 2010;23:165-9.
18. Franks SC, Sutton AJ, Bown MJ, Sayers RD. Systematic review and
meta-analysis of 12 years of endovascular abdominal aortic aneurysm
repair. Eur J Vasc Endovasc Surg 2007;33:154-71.
19. Leurs L, Buth J, Laheij R; for the EUROSTAR Collaborators. Long-
term results of endovascular abdominal aortic aneurysm treatment with
the ﬁrst generation of commercially available stent grafts. Arch Surg
2007;142:33-41.
20. van Marrewijk CJ, Leurs LJ, Vallabhaneni SR, Harris PL, Buth J,
Laheij RJ. Risk-adjusted outcome analysis of endovascular abdominal
aortic aneurysm repair in a large population: how do stent-grafts
compare? J Endovasc Ther 2005;12:417-29.
21. Pitolias GA, Schulte S, Donas KP, Horsch S. Secondary endovas-
cular and conversion procedures for failed endovascular abdominal
aortic aneurysm repair: can we still be optimistic? Vascular 2009;17:
15-22.
22. Verhoeven EL, Tielliu IF, Prins TR, Zeebregts CJ, van Andringa de
Kempenaer MG, Cina CS, et al. Frequency and outcome of re-
interventions after endovascular repair for abdominal aortic aneurysm:
a prospective cohort study. Eur J Vasc Endovasc Surg 2004;28:357-64.
23. Becquemin JP, Kelley L, Zubilewicz T, Desgranges P, Lapeyre M,
Kobeiter H. Outcomes of secondary interventions after abdo-
minal aortic aneurysm endovascular repair. J Vasc Surg 2004;39:
298-305.
24. Quinney BE, Parmar GM, Nagre SB, Patterson M, Passman MA,
Taylor S, et al. Long-term single institution comparison of endovas-
cular aneurysm repair and open aortic aneurysm repair. J Vasc Surg
2011;54:1592-7; discussion: 1597-8.
25. Brown LC, Powell JT, Thompson SG, Epstein DM, Sculpher MJ,
Greenhalgh RM. The UK EndoVascular Aneurysm Repair (EVAR)
trials: randomised trials of EVAR versus standard therapy. Health
Technol Assess 2012;16:1-218.
26. Abedi NN, Davenport DL, Xenos E, Sorial E, Minion DJ, Endean ED.
Gender and 30-day outcome in patients undergoing endovascular
aneurysm repair (EVAR): an analysis using the ACS NSQIP dataset.
J Vasc Surg 2009;50:486-91; 491.e1-4.
27. Leurs LJ, Visser P, Laheij RJ, Buth J, Harris PL, Blankensteijn JD.
Statin use is associated with reduced all-cause mortality after endovas-
cular abdominal aortic aneurysm repair. Vascular 2006;14:1-8.
Submitted Oct 2, 2012; accepted Jan 27, 2013.DISCUSSIONDr Fred Weaver (Los Angeles, Calif). Chang and his fellow
authors report a large EVAR experience over a 10-year period in
the Northern California Kaiser Permanente Hospital system.
During this period, 1736 EVARs were performed in the 17
hospitals of the Northern California Kaiser system. As the authors
point out, the strength of this report and analysis is that it
provides a real world experience from which to critically evaluate
the beneﬁt of EVAR in patients with abdominal aortic aneurysms.
The results they report are not dissimilar to what has been
previously reported from EVAR registries, single-institutionexperiences, and prospective randomized trials. Namely, they
report a perioperative mortality of 1.2%, a long-term reintervention
rate of 15%, a 3% late aneurysm-related mortality, and a discour-
aging 66% overall survival at 5 years. These results conﬁrm that,
at least during the last decade, EVAR technology has been safely
transferred from selected large academic and community hospitals
to multiple hospitals of varying sizes that comprise this integrated
health care system. One aspect of this report that demonstrates the
strength of working within an integrated hospital system with elec-
tronic records is the outstanding longitudinal graft surveillance rate
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332 Chang et al August 2013of 91.8%. I have four questions for the authors to begin discussion
of this ﬁne paper.
1. You report 16 type III endoleaks in your series, which is
almost 1% of the patients in this experience. Although this is
a small number, we have found type III endoleaks to be rare
if nonexistent in our own experience. Do you have any infor-
mation regarding the devices used, the experience of the oper-
ators who placed the devices, or other factors that could have
contributed to the type III endoleaks?
2. You report 22 conversions, 9 graft infections, and 22 late
ruptures. Do you have additional information on these
patients? Did the patients with late ruptures fall out of
surveillance, did they have identiﬁed endoleaks, or did the
ruptures occur without these factors? What about the graft
infections; do you think these infections were implant-related
or occurred by blood stream seeding remote from the time of
implantation?
3. Why in an integrated health care system, is the penetration of
statin use so low? You mention this in your manuscript, and in
fact, your sister Kaiser system in Southern California has re-
ported that statin use in patients with aortic aneurysms has
a positive effect on survival. Given the disappointing 66%
survival at 5 years and the potential beneﬁt of statins, does
your integrated health care system have a plan to improve
the penetration of statin use in the aortic aneurysm
population?
4. You mention in the manuscript that you do not have informa-
tion on device selection and to what extent the Instructions for
Use (IFU) was stretched to accommodate EVAR in certain
patients. Your ﬁnding that postprocedure endoleaks, speciﬁ-
cally type I and III, large aneurysm size, and urgent EVAR
contributed to late aneurysm-related mortality, suggests that
less than optimal patient selection by criteria of the IFU is
a possibility. I would like your thoughts as to how in your
particular hospital system patient selection and management
might be improved to minimize these factors that impacted
aneurysm-related mortality.
Dr Chang. Thank you, Dr Weaver, for your thoughtful
comments.
1. You report 16 type III endoleaks in your series, which is
almost 1% of the patients in this experience. Although this is
a small number, we have found type III endoleaks to be rare
if nonexistent in our own experience. Do you have any infor-
mation regarding the devices used, the experience of the oper-
ators who placed the devices, or other factors that could have
contributed to the type III endoleaks?
Dr Chang.We were surprised to note the number of type III
leaks as well. We are further investigating these cases and hope to
report on them soon. They occurred with all devices, but we saw
a concerning number of late suture-hole leaks that led to several
cases of sac expansion and rupture.
2. You report 22 conversions, 9 graft infections, and 22 late
ruptures. Do you have additional information on these
patients? Did the patients with late ruptures fall out of surveil-
lance, did they have identiﬁed endoleaks, or did the ruptures
occur without these factors? What about the graft infections;do you think these infections were implant-related or occurred
by blood stream seeding remote from the time of implantation?
Dr Chang. These patients are also the subject of a study in
progress. We have detailed follow-up on these patients and are in
the process of obtaining anatomic information that might help
explain the need for open conversions. Due to the vigilance of
our registry nurses, no patient who elected to be followed was
lost to follow-up, so we’re looking at other adverse events as factors
leading to rupture. In terms of graft infections, we’ll report the
details, but the cohort is likely too small to make general state-
ments. Most of these graft infections were remote from the time
of implantation.
3. Why in an integrated health care system, is the penetration of
statin use so low? You mention this in your manuscript, and
in fact, your sister Kaiser system in Southern California has re-
ported that statin use in patients with aortic aneurysms has
a positive effect on survival. Given the disappointing 66%
survival at 5 years and the potential beneﬁt of statins, does
your integrated health care system have a plan to improve the
penetration of statin use in the aortic aneurysm population?
Dr Chang. Dr Weaver brings up an excellent point. Statin
use has been shown to be protective in patients with AAAs as
well as with cardiovascular disease in general. Although not rep-
resented in this historical cohort, Kaiser Permanente has made
statin use a cornerstone of our cardiovascular risk reduction
strategy. Since the adoption of this risk reduction program in
2004, we’ve had a large increase in statin use along with other
emphasized interventions, leading to dramatic reductions in
MI- and CV-related death. Our EVAR cohort likely reﬂected
an earlier group of patients who may not have enjoyed the pro-
longed beneﬁts of statin use. I would anticipate a future analysis
of contemporary patients to show a salutary effect of these aggres-
sive interventions.
4. You mention in the manuscript that you do not have informa-
tion on device selection and to what extent the IFU was
stretched to accommodate EVAR in certain patients. Your
ﬁnding that postprocedure endoleaks, speciﬁcally type I and
III, large aneurysm size and urgent EVAR contributed to
late aneurysm-related mortality, suggests that less than optimal
patient selection by criteria of the IFU is a possibility. I would
like your thoughts as to how in your particular hospital system
patient selection and management might be improved to
minimize these factors that impacted aneurysm-related
mortality.
Dr Chang. We agree that the absence of anatomic informa-
tion is a key limitation of this manuscript. Without a correlation
of anatomic descriptors and adherence to IFU, it is difﬁcult to
comment on practice patterns and to correlate device-related
events that might affect patient survival. I think the ﬁrst step to
improving patient selection is to understand our outcomes and
to ﬁll in the appropriate knowledge gaps. In this regard, we have
created a national EVAR registry within Kaiser Permanente
(including Southern California, Hawaii, the Paciﬁc Northwest,
Colorado, and the Mid-Atlantic regions). Our dataset will incorpo-
rate anatomic factors in addition to procedure outcomes to help us
answer these important questions.
